BioCentury
ARTICLE | Product Development

CEPI’s biggest-ever award positions Novavax to scale up COVID-19 vaccine program

Novavax’s platform could offer a speedier alternative to traditional vaccine manufacturing

May 11, 2020 8:06 PM UTC
Updated on May 12, 2020 at 12:40 AM UTC

With an eye on a global supply, Novavax is setting itself up to produce more than 1 billion doses of its COVID-19 vaccine in 2021 as well as complete Phase II testing with a new infusion of up to $384 million from CEPI.

The funding -- the largest Coalition for Epidemic Preparedness Innovations has awarded to date -- brings the total Novavax Inc. (NASDAQ:NVAX) has received from CEPI to $388 million...